As a long term (approaching four years) Revlimid user, this Wall Street Journal story I read yesterday obviously concerns me, too:
Concerns Raised About Cengene Cancer Drug
BY JENNIFER CUMMINGS
NEW YORK—Studies showed a potential increase in the risk of secondary malignancies in patients taking Celgene Corp.’s multiple myeloma drug Revlimid for an extended period of time.
Two studies released at the American Society of Hematology over the past two days showed that patients in a group taking Revlimid as a maintenance therapy had a higher incidence of certain types of secondary cancers than a control arm.
Shares of Celgene were down 8.2% to $55.64 in midday trading on the Nasdaq Stock Market.
I haven’t had time to follow-up yet. But I wrote yesterday about “following the money” as we try to gauge which research news is likely to effect us most. This seems to be an example of that. A one day drop of 8.2% is HUGE!
Editor’s note: The 8.2% drop was recorded at midday. Celgene stock continued to fall, ending the trading day down 9.5%.
More as soon as I get details. I certainly haven’t received them yet through a Celgene company press release. Feel good and keep smiling! Pat